Statement Of Changes In Equity [Abstract]

ABIONYX Pharma - Filing #2813091

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-01-01
As at
2021-01-01
As at
2021-01-01
As at
2021-01-01
As at
2021-01-01
As at
2021-01-01
As at
2021-01-01
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity
7 169 EUR
2 726 EUR
192,000 EUR
8 599 EUR
229,000 EUR
1 418 EUR
126,000 EUR
201,000 EUR
169 829 EUR
10 677 EUR
10,000 EUR
179 214 EUR
87,000 EUR
1 396 EUR
5,000 EUR
39,000 EUR
1 232 EUR
6 629 EUR
164 822 EUR
170 322 EUR
136,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)
4 206 EUR
4 206 EUR
5 822 EUR
5 822 EUR
Comprehensive income
3 985 EUR
5 759 EUR
Issue of equity
8 892 EUR
164,000 EUR
9 056 EUR
Increase through other contributions by owners, equity
22,000 EUR
0 EUR
22,000 EUR
Increase (decrease) through treasury share transactions, equity
28,000 EUR
28,000 EUR
65,000 EUR
65,000 EUR
Increase (decrease) through share-based payment transactions, equity
505,000 EUR
505,000 EUR
815,000 EUR
815,000 EUR
Amount removed from reserve of change in value of time value of options and included in initial cost or other carrying amount of non-financial asset (liability) or firm commitment for which fair value hedge accounting is applied
170 804 EUR
0 EUR
170 804 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.